The combination of decitabine/cedazuridine and venetoclax achieved a 91% overall response rate in HR-MDS and CMML patients, with early responses observed. Median overall survival reached 30 months, ...

Ivo Carre, PhD, shares subgroup data that points to potential benefit in younger patients with high-risk MDS.

Sellas Life Sciences Group Inc. (NASDAQ:SLS) advanced 4% in premarket trading Monday after unveiling new Phase 2 data for its ...

AbbVie Inc (NYSE:ABBV) on Monday announced an update from the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine for newly diagnosed higher-risk myelodysplastic syndrome ...

AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall survival. The drugmaker ...

There is no standard treatment in acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) for patients who have a relapse following allogeneic hematopoietic cell transplantation. Patients who ...

Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. So, you know, I'm definitely most excited ...

ROCKVILLE, Md. and SUZHOU, China, June 02, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in ...

Scientists from the University of Texas MD Anderson Cancer Center say that they discovered that treatment resistance in patients with myelodysplastic syndromes (MDS) is caused by two distinct classes ...